Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 7/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25920363 | 0.84 | ALK (0.42) | CACNA2D1RXRAGRIN1GRIN2BMAOA | |
| SCHEMBL25584033 | 0.80 | ADRB2 (0.38) | RXRAGRIN1GRIN2BMAOANOTUM | |
| SCHEMBL25585949 | 0.78 | NOTUM (0.37) | RXRAGRIN1GRIN2BMAOANOTUM | |
| SCHEMBL25587990 | 0.73 | MIF (0.38) | RXRAGRIN1GRIN2BP2RX7MIF | |
| SCHEMBL7974222 | 0.71 | DDB1 (0.36) | CACNA2D1GRIN1GRIN2BMAOA | |
| SCHEMBL12964681 | 0.70 | P2RX7 (0.58) | RXRAGRIN1GRIN2BNOTUMP2RX7 | |
| SCHEMBL21322107 | 0.69 | CYP19A1 (0.40) | — | |
| SCHEMBL21133575 | 0.67 | CYP19A1 (0.44) | — | |
| SCHEMBL28337945 | 0.67 | DPP4 (0.49) | CACNA2D1RXRAGRIN1GRIN2BMAOA | |
| SCHEMBL12964599 | 0.67 | RXRA (0.54) | RXRAGRIN1GRIN2BNOTUMP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-13 | — | — | US | disclosed |
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | FUT6, DDOST, MGAM | CACNA2D1 4808/4885RXRA 2277/4885GRIN1 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.